14.66
-0.05 (-0.34%)
Penutupan Terdahulu | 14.71 |
Buka | 14.95 |
Jumlah Dagangan | 527,991 |
Purata Dagangan (3B) | 881,912 |
Modal Pasaran | 1,196,138,752 |
Harga / Jualan (P/S) | 3.54 |
Harga / Buku (P/B) | 2.88 |
Julat 52 Minggu | |
Tarikh Pendapatan | 6 Aug 2025 - 11 Aug 2025 |
Margin Operasi (TTM) | -130,369.45% |
EPS Cair (TTM) | -3.35 |
Jumlah Hutang/Ekuiti (D/E MRQ) | 3.82% |
Nisbah Semasa (MRQ) | 19.49 |
Aliran Tunai Operasi (OCF TTM) | -279.75 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -171.41 M |
Pulangan Atas Aset (ROA TTM) | -32.62% |
Pulangan Atas Ekuiti (ROE TTM) | -51.95% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Menurun | Menurun |
Biotechnology (Global) | Menurun | Menurun | |
Stok | Viridian Therapeutics, Inc. | Menurun | Menaik |
AISkor Stockmoo
Konsensus Penganalisis | 3.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | -1.0 |
Purata Bergerak Teknikal | -2.5 |
Osilator Teknikal | 0.5 |
Purata | 0.00 |
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED). |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Small Core |
% Dimiliki oleh Orang Dalam | 0.16% |
% Dimiliki oleh Institusi | 114.23% |
Pemilikan
Nama | Tarikh | Syer Dipegang |
---|---|---|
Commodore Capital Lp | 31 Mar 2025 | 3,600,000 |
Fairmount Funds Management Llc | 31 Mar 2025 | 3,445,813 |
Novo Holdings A/S | 31 Mar 2025 | 2,250,300 |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 45.00 (RBC Capital, 206.96%) | Beli |
Median | 36.00 (145.57%) | |
Rendah | 27.00 (Goldman Sachs, 84.18%) | Beli |
Purata | 36.00 (145.57%) | |
Jumlah | 5 Beli | |
Harga Purata @ Panggilan | 12.84 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
Needham | 20 May 2025 | 36.00 (145.57%) | Beli | 13.82 |
07 May 2025 | 36.00 (145.57%) | Beli | 12.29 | |
Goldman Sachs | 07 May 2025 | 27.00 (84.17%) | Beli | 12.29 |
JMP Securities | 07 May 2025 | 38.00 (159.21%) | Beli | 12.29 |
RBC Capital | 07 May 2025 | 45.00 (206.96%) | Beli | 12.29 |
HC Wainwright & Co. | 23 Apr 2025 | 34.00 (131.92%) | Beli | 13.51 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
05 Jun 2025 | Pengumuman | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
30 May 2025 | Pengumuman | Viridian Therapeutics to Participate in Upcoming June Investor Conferences |
20 May 2025 | Pengumuman | Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED) |
07 May 2025 | Pengumuman | Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED) |
06 May 2025 | Pengumuman | Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results |
02 May 2025 | Pengumuman | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
07 Apr 2025 | Pengumuman | Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |